WAM
NRSN icon

Warberg Asset Management’s NeuroSense Therapeutics NRSN Stock Holding History

Warberg Asset Management’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,700
Closed -$9.95K – 203
2025
Q1 		$9.95K Hold
10,700
– – ﹤0.01% 151
2024
Q4 		$12.8K Buy
+10,700
New +$12.3K ﹤0.01% 159
2022
Q1 		– Sell
-15,501
Closed -$38K – 246
2021
Q4 		$38K Buy
+15,501
New +$47.2K 0.01% 156

Other funds holding NRSN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Warberg Asset Management's NRSN Position: Q2 2025 in Review

Warberg Asset Management sold out of NeuroSense Therapeutics (NRSN) in Q2 2025, closing a stake of 10,700 shares — an estimated $9.95K sold.

Warberg Asset Management first reported a position in NRSN in Q4 2021 and held it in 3 quarters. The position peaked at $38K in Q4 2021. 17 funds tracked by Wall St. Rank hold NRSN as of Q2 2025.

  • Warberg Asset Management reported no remaining NeuroSense Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 10,700 NeuroSense Therapeutics shares in Q2 2025, an estimated $9.95K.
  • Warberg Asset Management first reported a position in NeuroSense Therapeutics in Q4 2021 and held it in 3 quarters.
  • Warberg Asset Management's NeuroSense Therapeutics position peaked at $38K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.